When does the weight loss plateau occur on drugs like Ozempic, and can you delay it?

Translate to Spanish or other 102 languages!

When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes
When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes

Medical News Today

- Advertisement -
  • A new study investigated why different obesity treatments, including diets, surgeries and new medications like GLP-1 receptor agonists, such as semaglutide and tirzepatide, lead to varying times at which weight loss plateaus.
  • Utilizing a mathematical model, the research examines how these interventions alter the body’s regulation of energy intake and expenditure, affecting the duration of effective weight loss.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/when-does-the-loss-plateau-occur-on-drugs-like-ozempic-and-can-you-delay-it

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Practical Health Tips to Navigate Cold and Flu Season Safely

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.
- Advertisement -